Mapi Pharma Begins Search For New Partners To Advance Long-Acting Depot Peptide Drugs Designed For Easy Self-Administration

Mapi Pharma Ltd., a fully integrated biopharmaceutical company in late-stage clinical development and focused on creating innovative long-acting depot injectable treatments, announced that it will participate in the 8th Annual Evercore Healthcare Conference, scheduled for December 2–4, 2025, in Miami, Florida. The company is currently looking to expand its partnerships for its new proprietary depot products. Mapi’s leadership team will be available for one-on-one meetings during the conference to discuss joint development opportunities. Interested organizations may contact Mapi directly or coordinate through their Evercore representative to arrange a discussion.

Mapi develops extended-release depot formulations backed by strong intellectual property, aiming to create lifecycle management solutions for both innovative and widely used pharmaceutical products across several therapeutic areas. The company’s lead asset, GA Depot for the treatment of Relapsing Forms of Multiple Sclerosis (RMS), is already under a full commercialization agreement. Additional pipeline programs in diabetes and schizophrenia have been funded through Phase II results.

The pipeline also features an injectable, long-acting version of Cariprazine developed using Mapi’s depot technology. Designed for once-monthly dosing, it aims to meet unmet needs in schizophrenia, bipolar I disorder, and major depressive disorder. Mapi recently initiated patient enrollment in a Phase I/II clinical study for this program.

As a fully integrated company specializing in depot pharmaceuticals, Mapi offers partners access to a range of advanced technologies and in-house capabilities. Its operations include dedicated depot formulation laboratories, a skilled clinical development team, and a large, GMP-approved manufacturing facility that supports both clinical and commercial production. This integration across R&D, clinical development, regulatory processes, and manufacturing enables Mapi to advance depot products efficiently and shorten time to market.

Ehud Marom, Chairman and Chief Executive Officer of Mapi Pharma, noted that the company has several strong partnering opportunities in development. These include Deutetrabenazine (AUSTEDO XR) Depot for Huntington’s disease and tardive dyskinesia, Anastrozole (Arimidex) Depot as an adjuvant therapy for postmenopausal women with hormone receptor-positive early breast cancer, as well as other promising candidates. He added that Mapi’s technologies can also support co-development of long-acting injectable versions of existing molecules for companies seeking to enhance their product lifecycle management strategies.